Breast cancer survival in the US and Europe: A CONCORD high‐resolution study

Allemani, Claudia; Sant, Milena; Weir, Hannah K.; Richardson, Lisa C.; Baili, Paolo; Storm, Hans H.; Siesling, Sabine; Torrella-Ramos, A.; Voogd, Adri C.; Aareleid, Tiiu; Ardanáz, Eva; Berrino, Franco; Bielska–Lasota, Magdalena; Bolick, Susan; Crimi, Claudia; Colonna, Marc; Contiero, Paolo; Cress, Rosemary D.; Crocetti, Emanuele; Fulton, John P.; Grosclaude, Pascale; Hakulinen, Timo; Izarzugaza, M. Isabel; Malmström, Per; Peignaux, K.; Primic-Žakelj, Maja; Rachtan, Jadwiga; Diba, C. Safaei; Sánchez, María José; Schymura, Maria J.; Shen, Tiefu; Traina, Adele; Tryggvadóttír, Laufey; Tumino, Rosario; Velten, Michel; Vercelli, Marina; Wolf, Holly J.; Woronoff, Anne Sophie; Wu, Xiao‐Cheng; Coleman, Michel P

doi:10.1002/ijc.27725

Cited by 104 publications

(79 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…59,70,82–84 High-resolution studies of tumour stage at diagnosis, treatment, and adherence to guidelines have helped account for international differences in survival. 55,85–87 The comparability of data gathered routinely on cancer stage remains poor in developed countries, 88 even though the TNM classification 89 has been available for more than 60 years. We will examine in more detail the extent to which available data on tumour stage can explain the very wide global differences in survival reported by us here.…”

Section: Discussionmentioning

confidence: 99%

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

et al. 2015

Self Cite

View full text Add to dashboard Cite

Summary Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15–99 years) and 75 000 children (age 0–14 years) diagnosed with cancer during 1995–2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005–09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10–20% between 1995–99 and 2005–09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995–99 and 2005–09 have generally been slight. For women diagnosed with ovarian cancer in 2005–09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005–09 was high (54–58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18–23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer surv...

show abstract

Section: Discussionmentioning

confidence: 99%

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…More detailed studies of survival, including information on stage at diagnosis and other clinical characteristics, will assist in better understanding of these disparities. 41,42 Much more research is needed.…”

Section: Discussionmentioning

confidence: 99%

Cancer survival in China, 2003–2005: A population‐based study

Zeng¹,

Zheng²,

Guo

et al. 2014

Intl Journal of Cancer

520

373

View full text Add to dashboard Cite

Limited population-based cancer registry data available in China until now has hampered efforts to inform cancer control policy. Following extensive efforts to improve the systematic cancer surveillance in this country, we report on the largest pooled analysis of cancer survival data in China to date. Of 21 population-based cancer registries, data from 17 registries (n 5 138,852 cancer records) were included in the final analysis. Cases were diagnosed in 2003-2005 and followed until the end of 2010. Age-standardized relative survival was calculated using region-specific life tables for all cancers combined and

show abstract

“…Breast cancer survival rates vary greatly worldwide, ranging from over 80% in North America and Western Europe, around 70% in Eastern Europe (Allemani et al, 2013), 90% in Hong Kong, 60% in Qidong, China, and 44% in Uganda (Sankaranarayanan et al, 2011). Survival of breast cancer in Songkhla in the period of 1990-1999 published in the book 'Cancer Survival in Africa, Asia, the Caribbean and Central America' was approximately 62.7% in middle-income countries and less than 40% in low-income countries.…”

Section: Discussionmentioning

confidence: 99%